STXS Stock Recent News

Stereotaxis (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. MAGiC Sweep is the world's first robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat complex arrhythmia patients.

ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments.

ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common stock in a registered direct offering, at a price per share of $2.00. The financing is being led by a strategic industry partner along with participation from a select group of institutional investors.

STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.

I rate Stereotaxis Strong Buy, with 85% upside to $4 PT, driven by underappreciated recurring revenue and regulatory catalysts. Recurring revenue is inflecting above 25% growth, with high-margin disposables and platform launches fueling a shift to an annuity-like model. Consensus underestimates top-line growth; I model $51M FY26E revenue, supported by robust operating momentum and innovation pipeline.

ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled “First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter,” the publication is the first peer-reviewed literature supporting the efficacy and safety of Stereotaxis' MAGiC catheter.

Stereotaxis, Inc. (NYSE:STXS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH Capital Partners Josh Jennings - TD Cowen Operator Good afternoon. Thank you for joining us for Stereotaxis' First Quarter 2025 Earnings Conference Call.

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago.

ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025.